
Exercise-related signaling
Human exercise observations measured naturally occurring MOTS-C. Participants were not given a MOTS-C injection.
Read the publication
Peptide care · Pen
A mitochondrial peptide studied in exercise biology. Animal treatment findings and measurements of naturally occurring MOTS-C in people are different kinds of evidence.
Suitability reviewed by a UAE-licensed physician
Confirm the dispensing pharmacy and preparation before treatment
Completing an assessment does not guarantee a prescription
Formats reflect the supplied catalog, not a prescription or confirmation of availability. Health topics describe scientific interest, not approved indications. Read the specific studies and preparation limits.
The role of this peptide
Metabolic and aging interests come from mitochondrial biology and animal exercise findings. They do not establish an injectable benefit in people.

Human exercise observations measured naturally occurring MOTS-C. Participants were not given a MOTS-C injection.
Read the publication
Treated mice showed changes in performance measures. Human improvement from a pen or vial has not been established by this work.
Read the publicationSafety & suitability
FDA reports insufficient human exposure information to assess MOTS-C safety and concerns about immunogenicity and peptide impurities.
Suitability depends on the specific preparation, intended use and clinical assessment. Product authorization must be verified separately from facility licensing.
The evidence
The human research measured the body’s own MOTS-C after exercise; it did not test a MOTS-C injection. Treatment findings in mice do not establish the same benefit in people.
Mice; exercise observations in 10 men · Experimental mouse treatment; no human administration
The human observations do not demonstrate benefit or safety from administering MOTS-C.
The human part of the highlighted study measured the body’s own MOTS-C after exercise. Participants were not treated with a MOTS-C pen or vial. Studies of analogs are separate.
Reviewed September 15, 2026. Selected publications, not a systematic review. Findings do not establish product authorization.
Our review approachFor your consultation
Three questions to help you discuss MOTS-C. Your clinician decides which preparation, checks and follow-up are relevant.
The preparation
What is the exact ingredient, formulation and strength, and how would it be used?
Your assessment
Would blood glucose, HbA1c or a lipid profile help assess my metabolic health?
Your follow-up
What would count as a meaningful benefit, when would we review it, and which side effects should I report?
These questions are not a dosing schedule or a required test panel. Your clinician individualizes the plan.
A peptide name is only the beginning. The preparation, clinical need and available evidence all matter to the decision.

Medical Director & Physician, DarDoc

Physician, DarDoc
Discuss the symptoms or diagnosis behind your interest in a peptide, alongside current medicines and previous treatment.
Consider the evidence for its route and intended use, its regulatory status, and established treatment alternatives.
Discuss potential benefits, uncertainties and risks. A prescription is considered only when clinically appropriate and permitted.
If treatment is prescribed, agree on monitoring, side effects to report and when to reassess the plan.
SCOPE credentials shown relate to obesity medicine, not peptide-specific certification. The treating physician is confirmed at booking.
A few things to know
Your physician reviews your symptoms, history, current medicines and goals. The discussion should include the specific evidence, risks, alternatives and a follow-up plan before any treatment decision.
The human part of the highlighted study measured the body’s own MOTS-C after exercise. Participants were not treated with a MOTS-C pen or vial. Studies of analogs are separate.
FDA reports insufficient human exposure information to assess MOTS-C safety and concerns about immunogenicity and peptide impurities.
Prescription treatment is considered only after clinical assessment. Browsing a format does not select a dose, determine eligibility or guarantee a prescription.
Continue exploring
Explore other compounds discussed in these health topics, with the evidence for each.
Healthy aging · Sleep & focus
Cell studies examine telomerase activity. An older clinical report explored a retinal condition, but human longevity benefits remain unestablished.
Recovery · Metabolism
Controlled studies show that long-acting CJC-1295 can increase growth hormone and IGF-1 levels in healthy adults.
Recovery · Metabolism
Human studies measured growth-hormone release. A trial after bowel surgery did not establish faster recovery of eating.
Bring your questions
Want to understand where MOTS-C fits? Discuss the evidence, your health history and the options with DarDoc.